Skip to content
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
Menu
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact

About TriSalus

We have a singular purpose—to help more patients with liver and pancreatic tumors benefit from immunotherapy treatments.

Our Company

TriSalus Life Sciences® was created in 2018 to develop and commercialize an innovative approach for the treatment of liver and pancreatic tumors. Our platform approach addresses immune dysfunction in liver and pancreatic tumors by combining immunotherapy drugs with highly effective drug delivery technology. Our company’s heritage is in the development of devices for our Pressure-Enabled Drug Delivery™ (PEDD™) method. Building on this history, we launched our new platform in 2020 with the acquisition of SD-101. SD-101 is an investigational toll-like receptor 9 (TLR9) agonist with the potential to modulate the immune system to enable immunotherapy.

TriSalus’ vision is based on nearly twenty years of work by Steven Katz, MD, now Chief Medical Officer of TriSalus and Chairman of our Scientific Advisory Board. Mary Szela, our Chief Executive Officer, brings deep experience in commercial and clinical fields. TriSalus is quickly expanding to meet its mission, with a strong management group leading our manufacturing, R&D, clinical and commercial teams.

Our Leadership

Our team brings a powerful combination of proven clinical, strategic and commercial capabilities and a passion for developing solutions that positively impact the lives of patients.

SENIOR MANAGEMENT
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARDS

Mary Szela

Chief Executive Officer and President

Mary Szela has nearly 35 years of experience in both the commercial and clinical arenas. Her accomplishments in building billion-dollar businesses, turning around faltering businesses, igniting growth in stagnant businesses and devising innovative, differentiated strategies for undistinguished products make for a remarkable record.

Mary is currently CEO of TriSalus Life Sciences, an immuno-oncology company focused on transforming the way liver and pancreatic tumors are treated. The platform integrates a drug delivery technology with SD-101, a toll-like receptor 9 agonist and other pipeline assets in combination with checkpoint inhibitor therapy to improve patient response rates.

Previously, Mary served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company’s revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus).

Mary held ascending management positions at Abbott Laboratories including President of the company’s $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Senior Vice President for global strategic marketing and services. Mary currently serves as a member of the Board of Directors for Kura Oncology, Prometheus Biosciences, Omega Therapeutics, Senda Biosciences and TriSalus Life Sciences.

She earned an MBA and a BS in nursing, both from the University of Illinois.

Steven C. Katz, MD, FACS

Chief Medical Officer, Scientific Advisory Board Chairman

Dr. Steven C. Katz joined TriSalus in 2018 as Chief Medical Advisor and Chairman of the Scientific Advisory Boards. In September 2020, Steven became the first Chief Medical Officer of TriSalus. Previously, as a full-time academic surgical oncologist, he developed a reputation as a leader in solid tumor immunotherapy, cellular therapeutics, cancer biology, liver immunology and execution of immunotherapy clinical trials. His laboratory has focused on studying liver immunosuppressive cells and strategies for enabling immunotherapy in liver tumors. He also currently serves as Associate Professor of Surgery at the Warren Alpert Medical School of Brown University. His clinical expertise is in the surgical therapy and multi-disciplinary management of liver tumors, pancreas tumors, sarcoma and melanoma.

Steven attended the New York University School of Medicine, received the Alpha Omega Alpha Award, and was inducted into the Alpha Omega Honor Society. He completed his general surgery residency at the New York University Medical Center and was appointed as the Chief Resident. His training included two-year fellowships in Immunology and then Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow. Steven earned his Bachelor of Arts degree at Wesleyan University in Middletown, CT, with a double-major in molecular biology/biochemistry and government.

Steven has received research grants from numerous societies, the NIH and DOD. He has led five solid tumor CAR-T clinical trials, testing novel delivery approaches. He serves as a reviewer for several scientific journals and has served on numerous editorial boards. Steven also participates in NIH study sections and American Board of Surgery exam committees.

Sean Murphy

Chief Financial Officer, Director

Sean Murphy joined TriSalus as Chief Financial Officer in June 2022. Sean has 40+ years of experience in healthcare operations and business development, encompassing pharmaceuticals, medical devices, and diagnostics. He was appointed a director of TriSalus in September 2021, after serving as Executive Vice President of Malin Life Sciences Holdings. A publicly traded investment company, Malin invested in a portfolio of companies that included pharmaceuticals, medical devices, and healthcare services. Additionally, Sean has been a Senior Advisor at Evercore Partners, a leading investment-banking advisory firm. He was also Head of Corporate M&A and Business Development at Abbott Laboratories, where, over 30 years with the company, he played a leading role in strategic and operational investments. Currently, he serves on the board of directors of several life science companies, including Radius Health, Immucor Diagnostics, Xenex and Prenosis.

A CPA, Sean earned an MS in Finance from the University of Illinois and a BBA from Western Illinois University.

Jim Alecxih

President Device Technology

Jim Alecxih has more than 30 years of experience in all aspects of business, focused primarily on biotechnology and medical devices. His expertise includes product development and launch, as well as highly successful international and domestic go-to-market strategies.

Jim is President, Device Technology, for TriSalus Life Sciences, an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. He is responsible for overseeing the growth and development of TriSalus’ TriNav® Infusion System, including device engineering, quality, sales, marketing, and market access.

Prior to joining TriSalus, Jim served as President and CEO at ViveBio Scientific, a biotechnology company focused on specimen transportation and storage, where he raised funding to enable regulatory clearance, manufacturing, and commercialization of a propriety blood plasma separation device. As Chief Commercial Officer of ViewRay, an early-stage radiation oncology company, he led all commercial strategies. Jim spent most of his professional career at Intuitive Surgical, known for their minimally invasive da Vinci surgical systems, where he led successful domestic and international sales teams and exceeded revenue budgets for 51 consecutive quarters over a 14-year period, enabling significant revenue growth for the company.

Jim earned his BA in business administration from LeTourneau University in Longview, Texas.

Bryan F. Cox, PhD

Chief of Research

Dr. Bryan F. Cox joins TriSalus as Chief of Research with an emphasis on pharmaceuticals. Bryan's extensive experience working with due diligence teams as they determine the best path forward from early discovery to first-in-man studies, including involvement in projects resulting in U.S. FDA regulatory approval such as Baxalta®, Gocovri®, Giapreza®, Tricor® and Orilissa®. He has (co-) authored/approved over 250 documents for Regulatory submission and participated in the advancement of over 60 compounds to Phase I clinical trials.

Prior to TriSalus, Bryan was President of CoPharm Global Consulting and spent 17 years at Abbott/Abbvie as Director of Integrative Pharmacology, responsible for both lead optimization and IND-enabling studies. In addition, he was a charter member of the technical assessment team for Abbott BioVentures and spent over 20 years serving on their due diligence teams. Prior to joining Abbott, Bryan was with Rhone Poulenc Rorer. He has published more than 100 papers in peer reviewed journals and has twice been elected to the Council for the American Society of Pharmacology and Experimental Therapeutics.

Bryan received his PhD in Pharmacology from the University of Iowa and is currently an adjunct Professor of Pharmacology at the University of Iowa, College of Medicine.

Jennifer L. Stevens, JD

Chief Regulatory Officer

Jennifer L. Stevens joined TriSalus in March 2021 and serves as Chief Regulatory Officer. Her responsibilities include leading Regulatory Affairs Strategy and Quality Assurance for both the drug and device components of the business. Jennifer brings us expertise in regulatory affairs, law and policy developed during nearly 30 years of advising clients as a regulatory leader in industry, a regulator at the FDA, and an attorney/partner in several law firms, including Kirkland & Ellis, Willkie, Farr & Gallagher, and Pillsbury, where her work included both compliance counseling and transactional work for clients in regulated industries.

Most recently, Jennifer was Executive Director, Immuno-Oncology/Oncology, Global Regulatory Affairs at EMD Serono (Merck KGaA) where she had oversight responsibility for early and late-stage immuno-oncology/oncology assets. Her accomplishments included regulatory approvals globally for Bavencio, an anti-PD1 therapy being developed in collaboration with Merck KGaA/Pfizer, including BLAs/sBLAs (Merkel Cell carcinoma, 2L urothelial carcinoma (UC), Renal Cell carcinoma, and 1L UC maintenance). Jennifer also conducted due diligence for in-licensing/purchase of early/mid/late stage assets.

Prior to joining the pharma industry, Jennifer spent nearly 5 years as Counsel at the FDA, advising on regulations, policy, and agency guidance.

Jennifer received her bachelor’s degree from the University of Illinois and her JD from George Washington University, graduating cum laude from both institutions.

Richard B. Marshak VMD, MBA

Senior Vice President Business Development & Strategy

Dr. Richard B. Marshak joined TriSalus in June 2022 and serves as Senior Vice President, Business Development & Strategy. Richard’s focus is leading the planning and execution of TriSalus’s critical business development and partnership efforts while also envisioning and guiding the SD-101 go-to-market strategy. Richard brings nearly 25 years of experience in the pharmaceutical and biotech space, spanning early discovery through commercialization. During this time, he led a broad range of strategic transactions and had major roles in more than 13 product launches while at Abbott.

Prior to joining TriSalus, Richard was Managing Principal of LF Consulting, providing strategic consulting services to a range of companies, helping to guide critical decisions around product development, corporate development, and commercialization strategies. Richard also served as an Advisor to EMA Partners, a boutique investment bank. During this period he co-founded and served as Chief Business Officer at Nephraegis Therapeutics where he remains on the board of directors. He also served as CEO of Mount Tam Biotechnologies, a biotechnology company spun out of the Buck Institute for Research on Aging, focused on developing novel mTOR modulators to improve the health and well-being of patients suffering from a range of serious diseases.

Prior to this Richard spent 15 years at Abbott/Abbvie in roles spanning marketing, business development, strategic planning, and general management in the Pharmaceutical Products Group. These included General Manager of the Pain Care Franchise and General Manager Alliance Management & Strategic Planning where responsibilities included US business development and global commercial assessment of all licensing opportunities.

Before his time in the pharmaceutical industry, Richard was an equine veterinarian in Pennsylvania. He holds VMD and BA degrees from the University of Pennsylvania and an MBA from the University of Chicago’s Booth School of Business.

Mats Wahlström

Chairman of the Board

Mats Wahlstrom has more than 37 years of experience in the healthcare industry, having served as CEO and CFO of large international companies in the renal field.  Mats currently serves as Executive Chairman of KMG Capital Partners, LLC, Chairman of Breakout Investment Partners, LLC, Chairman of Caduceus Medical Holdings, Inc., and Chairman of Triomed AB, a medical device company. He also serves as the Lead Director of Coherus Biosciences, Inc., a public biotech company. In addition, he serves on the boards of Alteco Medical AB, a public medical device company, and Circuit Clinical Solutions, Inc., a clinical research company.

Mats has also served as a director of Healthgrades, Inc., Zynex, Inc., and Getinge AB, all public companies in the healthcare industry.  From January 2004 through December 2009, Mats served as Co-CEO of Fresenius Medical Care North America, and from November 2002 through December 2009 as President and CEO of Fresenius Medical Services, the largest dialysis provider in the U.S.  Prior to joining Fresenius Medical Care in 2002, he held various positions at Gambro AB in Sweden, including 10 years as CEO of Gambro North America and Gambro Healthcare, Inc., as well as CFO and Executive Vice President of the Gambro Group.

Kerry Hicks

Director

Kerry Hicks currently serves as CEO and President of KMG Capital Partners LLC, a boutique healthcare venture capital company based in Denver, Colorado. As a successful, innovative healthcare executive, Kerry leverages his extensive healthcare and leadership expertise to provide strategic guidance and drive success within portfolio companies.

Prior to joining KMG Capital Partners, Kerry was Founder, Chairman (1998 – 2010) and Chief Executive Officer (1998 – 2012) of Healthgrades. He led Healthgrades through eleven years of consistent growth as a publicly traded company, and then facilitated the sale of the business to Vestar Capital Partners in 2010. Under his leadership, Healthgrades transformed into the premier destination for consumers seeking information on doctors and hospitals. Kerry built Healthgrades from a predecessor company, Specialty Care Network, where he served as President and Chief Executive Officer from 1995 to 1999. From 1985 to 1995 he served as Senior Vice President of LBA Healthcare.

Kerry currently serves as Executive Chairman of Circuit Clinical, Co-Chairman of Breakout Investment Partners, LLC, and serves on the boards of KMG Capital Partners LLC, Caduceus Medical Holdings, Inc. and TriSalus Life Sciences, as well as the Advisory Council of the Institute for Entrepreneurship at Colorado State University, and as a Senior Advisor to both Kitchen One- For-One and the SOX Place, which provide services to at-risk populations in the Denver area.

Diane Parks

Director

Diane Parks joins the TriSalus board with more than 30 years of expertise across the biotech, pharmaceutical, and advertising industries. She’s held executive roles at Kite Pharma Inc, Pharmacyclics, Amgen, and Genentech, most recently serving as senior vice president, marketing and account management at Kite Pharma Inc. Ms. Parks is credited with successfully leading the launch of the first-ever CAR-T therapy, YESCARTA.

She holds a Master of Business Administration degree from Georgia State University and received her Bachelor of Arts degree from Kansas State University. Diane currently serves on several other boards including Calliditas Therapeutics, Kura Oncology, CTI BioPharma and Soligenix, all early-stage biotechnology companies.

Anil Singhal

Director

Dr. Anil Singhal is currently the President and Chief Executive Officer of Trishula Therapeutics, a privately held, clinical-stage company developing TTX-030, a CD39 antibody in multiple solid tumors. Previously, he held a similar role at Adicet Bio, a company developing allogeneic cell therapy in cancer.  He joined Adicet from Canaan Partners where he served as Executive in Residence and OncoResponse Inc., where he served as Chief Scientific Officer. He is the former Vice President of Early Oncology Development of AbbVie and Head of its Abbvie-Redwood City, California site. During his tenure at AbbVie, Anil oversaw the global regulatory approval of Empliciti in multiple myeloma and Daclizumab in multiple sclerosis. As a member of the R&D leadership team, he helped to guide an impressive portfolio and key translational science capabilities in oncology and other diseases.

Anil has held senior roles in the U.S., Japanese and German biopharma/biotechnology industry leading to the approvals of Prosorba in auto-immune disease and talaporfin sodium in non-small cell lung cancer. Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at the University of Washington.

Simone Song

Director

Simone Song is the founder of ORI Capital, and the senior partner of ORI Healthcare Funds which focuses on investing in early-stage and innovative healthcare companies globally.

Simone is the architect of ORIzon, a big data-driven AI research platform which enables ORI Capital to become a quantitative venture capital fund manager that combines quantitative analysis with fundamental research.

Simone serves on the boards of directors of various investee companies of ORI Healthcare Funds, including being the chairman of AffyImmune and being the directors of CG Oncology, Enable Injections, Pillar Biosciences and TriSalus.

Simone was the former Head of Goldman Sachs Healthcare Investment Banking for Greater China. Prior to joining Goldman Sachs, she was a Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers and an executive board advisor to AXA Asia Pacific Holdings.

Simone received a BA in Economics from Fudan University in China and a MA in Economics from Claremont Graduate School.

John L. Tullis

Director

John L. Tullis is CEO at Tullis Health Investors, an institutional investment fund manager focused on rapidly growing, primarily private, emerging healthcare companies with breakthrough innovations.  His focus is to create impact by helping companies accelerate the process of scaling their technologies, therapies, and services into widespread commercial markets.  He has more than 26 years of investing experience. John currently serves as an independent board member of Intrivo Diagnostics.  He was also an Executive Committee Member of the Board of Directors of the Beacon Council, Miami-Dade’s Economic Development Organization, for three years.

John holds a Bachelor’s degree in Liberal Arts from DePauw University. He received a Graduate Certificate from the University of Virginia’s McIntire Business Institute and a Master’s degree in Business Administration from the University of Miami.

Sean Murphy

Chief Financial Officer, Director

Sean Murphy joined TriSalus as Chief Financial Officer in June 2022. Sean has 40+ years of experience in healthcare operations and business development, encompassing pharmaceuticals, medical devices, and diagnostics. He was appointed a director of TriSalus in September 2021, after serving as Executive Vice President of Malin Life Sciences Holdings. A publicly traded investment company, Malin invested in a portfolio of companies that included pharmaceuticals, medical devices, and healthcare services. Additionally, Sean has been a Senior Advisor at Evercore Partners, a leading investment-banking advisory firm. He was also Head of Corporate M&A and Business Development at Abbott Laboratories, where, over 30 years with the company, he played a leading role in strategic and operational investments. Currently, he serves on the board of directors of several life science companies, including Radius Health, Immucor Diagnostics, Xenex and Prenosis.

A CPA, Sean earned an MS in Finance from the University of Illinois and a BBA from Western Illinois University.

Mary Szela

Chief Executive Officer and President

Mary Szela has nearly 35 years of experience in both the commercial and clinical arenas. Her accomplishments in building billion-dollar businesses, turning around faltering businesses, igniting growth in stagnant businesses and devising innovative, differentiated strategies for undistinguished products make for a remarkable record.

Mary is currently CEO of TriSalus Life Sciences, an immuno-oncology company focused on transforming the way liver and pancreatic tumors are treated. The platform integrates a drug delivery technology with SD-101, a toll-like receptor 9 agonist and other pipeline assets in combination with checkpoint inhibitor therapy to improve patient response rates.

Previously, Mary served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company’s revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus).

Mary held ascending management positions at Abbott Laboratories including President of the company’s $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Senior Vice President for global strategic marketing and services. Mary currently serves as a member of the Board of Directors for Kura Oncology, Prometheus Biosciences, Omega Therapeutics, Senda Biosciences and TriSalus Life Sciences.

She earned an MBA and a BS in nursing, both from the University of Illinois.

Scientific Advisory Board - Oncology

Richard D Carvajal, MD

Scientific Advisory Board Member

Dr. Richard D. Carvajal is an Associate Professor of Medicine at Columbia University Irving Medical Center where he serves as both Director of Experimental Therapeutics and Director of the Melanoma Service within the Division of Hematology/Oncology. He serves as Co-Leader of the Precision Oncology and Systems Biology Program within the Herbert Irving Comprehensive Cancer Center.

Richard’s research is focused on the development of novel therapies for patients with melanoma and other cancers, with the overall objective of controlling and curing these diseases. To achieve this goal, he has used our increasing knowledge of the underlying biology of cancer to rapidly integrate this knowledge, novel targeted and immunotherapeutic agents, and efficient trial design in order to improve the outcomes of cancer patients everywhere. Richard's melanoma research has included the study and treatment of uncommon clinical and molecular subsets of melanoma such as melanomas arising from the eye (uveal melanomas), from the mucosal surfaces of the body (mucosal melanomas), and from the palms of the hands, soles of the feet or under the fingernails (acral melanomas).

He has been the principal investigator or co-investigator of over 500 clinical trials, including a number of investigator-initiated, multi-center, Cancer Therapy Evaluation Program (CTEP) sponsored and industry-supported clinical trials. His research has been supported by the National Cancer Institute, the Food and Drug Administration, the Conquer Cancer Foundation, the Melanoma Research Alliance, the Melanoma Research Foundation and the Empire Clinical Research Investigator Program. He has authored or co-authored more than 200 peer-reviewed manuscripts, books, and book chapters.

In addition to Richard's work at Columbia University Irving Medical Center, he serves as the co-chair of the International Rare Cancer Initiative Uveal Melanoma working group, a joint initiative between the National Cancer Institute, the European Organization for Research and Treatment of Cancer, and the Cancer Research UK to enhance international collaboration in the conduct of clinical trials for uveal melanoma.

Christopher Crane, MD

Scientific Advisory Board Member

Dr. Christopher Crane is a Vice Chair of the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) specializing in gastrointestinal cancers. Prior to joining MSKCC, he served as Program Director/Chief of the Gastrointestinal Section, and Program Director of the Residency and Fellowship training programs in the Department of Radiation Oncology at the University of Texas M. D. Anderson Cancer Center.

Christopher is leading several cancer clinical trials across the country. He is interested in the role of radiation dose escalation using novel technologies in the treatment of liver and pancreatic cancers. He has helped develop technologies that allow administration of higher doses of radiation in GI malignancies and states that technology such as image guidance has helped with the challenge of internal organ motion.

Christopher has been involved with the NCI-Gastrointestinal Steering Committee, NRG Oncology Group, ASTRO, ASCO, Locally advanced and Advanced Pancreatic Clinical Practice Guidelines and the Emeritus Scientific and Medical Advisory Board of PANCAN.

Sapna Patel, BA, MD

Scientific Advisory Board Member

Dr. Sapna Patel is a medical oncologist and Associate Professor, Director of the Uveal Melanoma Program, and Melanoma Fellowship Program Director at the University of Texas MD Anderson Cancer Center in Houston, Texas specializing in uveal, cutaneous, and mucosal melanoma with one of the largest metastatic uveal melanoma practices in the world.

Sapna has led several investigator-initiated and multi-institutional clinical trials, including studies of targeted therapy, immunotherapy, T-cell therapy, and antibody-drug conjugates for uveal melanoma. Her lab work focuses on translational research, characterizing longitudinal molecular signatures in tumor samples from patients receiving treatment. She also leads several cutaneous melanoma projects with SWOG and serves as Melanoma Chair for SWOG. She has received intramural and extramural funding including NIH grants. Her goal is to develop effective therapies for adjuvant and metastatic settings, and to identify biomarkers to predict clinical benefit.

Vincent Picozzi, MD

Scientific Advisory Board Member

Dr. Vincent J. Picozzi is Director for the Pancreaticobiliary Program at Virginia Mason Medical Center. A summa cum laude, Phi Beta Kappa graduate from Yale University, Vincent obtained his MD degree from Stanford University, did his internship and residency at Harvard University (Brigham and Women's Hospital) and fellowships in hematology and oncology again at Stanford. He also holds a Master’s degree in Medical Management, Delta Omega, from Tulane University. Vincent was an instructor in hematology and oncology at Stanford for two years before joining Virginia Mason, where he has been for the past 36 years.

Vincent has one of the largest pancreaticobiliary oncology practices in the United States. He has received numerous accolades as a clinician, including designation as one of Seattle’s Best Doctors and one of America’s Top Cancer Doctors for the last fifteen consecutive years (2008-2022). He also directs an active, comprehensive clinical and translational research program in pancreaticobiliary cancer at Virginia Mason and has published nearly 200 papers and abstracts.

Vincent has educational committees for the GI Oncology Symposium and ASCO for non-colorectal cancers and served as Educational Chair for both in 2016. He has been a featured speaker at virtually every major clinical oncologic meeting in the United States, including ASCO (the American Society of Clinical Oncology), ASH (the American Society of Hematology), ASTRO (the American Society of Therapeutic Radiation Oncology), Digestive Diseases Week, AHPBA (The American Hepatopancreaticobiliary Association), ACOS (the American College of Surgeons), the Best of ASCO, the GI Oncology Symposium and the World Pancreas Symposium.

Vincent also has held a number of leadership positions with national and regional organizations, including ASCO, ASH, the American College of Surgeons Oncology Group (ACOSOG), the Pancreatic Cancer Action Network where he is a past chairman and current board member for the Scientific and Medical Advisory Board, the Pancreas Cancer Research Team (PCRT-Executive Committee) and the Providence Hospice of Seattle (Executive Board). He also has proudly served on the Executive Board of the Washington State Medical Oncology Society since its inception 30 years ago, twice serving as president. Recently, Vincent is the co-principal investigator and Clinical Trials Consortium chairman of the new Precision Promise Clinical Research Consortium sponsored by the Pancreatic Cancer Action Network.

Venu G. Pillarisetty, MD

Scientific Advisory Board Member

A Professor of Hepatopancreatobiliary Surgical Oncology at the University of Washington and the Fred Hutchinson Cancer Center, Dr. Venu G. Pillarisetty treats patients with pancreatic cancer and other diseases involving the pancreas. He attended Columbia University College of Physicians and Surgeons, did his General Surgery residency at the University of Massachusetts, and completed fellowships in Tumor Immunology and Surgical Oncology at Memorial Sloan-Kettering Cancer Center prior to joining the faculty at the University of Washington.

Funded by the NIH, the DoD, and several industry partnerships, Venu's research laboratory work using cultured slices of fresh human tumors has revealed unique targetable aspects of tumor immunobiology. As a clinical trialist, he is actively working to translate his laboratory findings to patient care through NIH cooperative group studies.

Marlana M Orloff, MD

Scientific Advisory Board Member

Dr. Marlana Orloff is an associate professor of medicine and medical oncologist at Thomas Jefferson University Hospital – Sidney Kimmel Cancer Center in Philadelphia, PA. Her clinical and research focus is on primary and advanced melanomas. Her main interest is in rare melanomas including uveal, conjunctival and mucosal melanoma.

Marlana's research is centered on investigating the epidemiology of uveal melanoma and discovery of novel therapies for primary and advanced uveal, conjunctival, mucosal and cutaneous melanoma. She works very closely with the team at Wills Eye Hospital to manage hundreds of patients with primary and metastatic ocular melanoma. Marlana is a member of a multidisciplinary team of medical oncologists, interventional radiologists, radiation oncologist and numerous other essential personnel that treats patients with metastatic uveal melanoma from all over the country. She is principal and co-investigator on a number of clinical trials enrolling patients with primary and advanced melanomas of all types.

Mike Pishvaian, MD, PhD

Scientific Advisory Board Member

Dr. Mike Pishvaian is an Associate Professor in the Department of Oncology at Johns Hopkins University.  Mike is an MD and has a PhD in Tumor Biology, having earned both degrees at Georgetown in 2001.  He remained at Georgetown after graduation, completing his medical residency in 2004, then his fellowship in Hematology/Oncology in 2007.  He served on the faculty at Georgetown until moving to MD Anderson in 2019.  At MD Anderson, he was the co-director for Clinical Research at the Zayed Center for Pancreatic Cancer Research.  He then moved to Johns Hopkins, and is the Director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs at the National Capital Region Cancer Center.

Mike is a translational oncologist, focused on providing novel therapies for patients, particularly in the areas of pancreatic cancer and refractory colorectal cancer.  His work has been focused in the area of precision medicine, with a special focus on therapy targeted towards homologous recombination DNA repair deficient tumors, and Mike is a Co-investigator on an NIH RO1 to study mechanisms of resistance to PARP inhibitor-based therapy, and a Co-PI of a U01 grant aimed at studying ex vivo patient derived models of cancer for patients with pancreatic cancer.

Steven C. Katz, MD, FACS

Chief Medical Officer, Scientific Advisory Board Chairman

Dr. Steven C. Katz joined TriSalus in 2018 as Chief Medical Advisor and Chairman of the Scientific Advisory Boards. In September 2020, Steven became the first Chief Medical Officer of TriSalus. Previously, as a full-time academic surgical oncologist, he developed a reputation as a leader in solid tumor immunotherapy, cellular therapeutics, cancer biology, liver immunology and execution of immunotherapy clinical trials. His laboratory has focused on studying liver immunosuppressive cells and strategies for enabling immunotherapy in liver tumors. He also currently serves as Associate Professor of Surgery at the Warren Alpert Medical School of Brown University. His clinical expertise is in the surgical therapy and multi-disciplinary management of liver tumors, pancreas tumors, sarcoma and melanoma.

Steven attended the New York University School of Medicine, received the Alpha Omega Alpha Award, and was inducted into the Alpha Omega Honor Society. He completed his general surgery residency at the New York University Medical Center and was appointed as the Chief Resident. His training included two-year fellowships in Immunology and then Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow. Steven earned his Bachelor of Arts degree at Wesleyan University in Middletown, CT, with a double-major in molecular biology/biochemistry and government.

Steven has received research grants from numerous societies, the NIH and DOD. He has led five solid tumor CAR-T clinical trials, testing novel delivery approaches. He serves as a reviewer for several scientific journals and has served on numerous editorial boards. Steven also participates in NIH study sections and American Board of Surgery exam committees.

Scientific Advisory Board - Radiology

Jordan Tasse, MD

Scientific Advisory Board Member

Dr. Jordan Tasse is the director of interventional oncology and an associate professor of vascular and interventional radiology at Rush University Medical Center in Chicago, Illinois.  His practice focuses on minimally invasive cancer treatments throughout the body including the liver, lung,  pancreas and kidney. Jordan is currently involved in multiple clinical research projects including trans-arterial cancer therapies, ablative treatments and immunotherapy.

Terence Gade, MD, PhD

Scientific Advisory Board Member

Dr. Terence Gade is Assistant Professor of Radiology, Penn Presbyterian Medical Center, Attending, Hospital of the University of Pennsylvania, and Assistant Investigator, Abramson Cancer Research Institute. Terence co-founded the Penn Image-Guided Interventions (PIGI) Laboratory. The interests of the laboratory focus on translational research for the development of novel imaging approaches and advanced therapeutics.

Ripal Gandhi, MD

Scientific Advisory Board Member

Dr. Ripal Gandhi did his undergraduate studies at Northwestern University and Harvard University. He graduated summa cum laude (highest honors). He received his degree in medicine from Northwestern University Medical School, where he also graduated with honors. Following medical school, he completed a surgical internship at Cornell University Medical Center and New York Presbyterian Hospital. He completed his residency training and fellowship at UCLA Medical Center. Currently, he is an associate clinical professor at the University of South Florida School of Medicine and FIU Herbert Wertheim College of Medicine. Ripal regularly trains other physicians in various vascular/endovascular, interventional radiology, and interventional oncology techniques.

Because of his interest in discovering new therapies, Ripal also dedicated an entire year to biomedical research at the renowned Memorial Sloan-Kettering Cancer Center in New York. At Sloan-Kettering, he investigated chemoembolization and other minimally invasive therapies for liver cancer and other malignancies. He also served as a research fellow at the National Institutes of Health (NIH). He has published his findings in several scientific journals, including the Journal of Vascular and Interventional Radiology, Journal of Vascular Surgery, Vascular Medicine, Interventional Cardiology, and Journal of the American College of Surgeons. He also authored several textbook chapters and presented his research at national and international meetings.

Prior to joining Miami Cardiac & Vascular Institute, he was an international visiting scholar at Asan Medical Center/University of Ulsan Medical School in Seoul, South Korea. As an international scholar, he gave several lectures and furthered his expertise in innovative minimally invasive therapies.

Ripal is the recipient of multiple awards, including the American College of Physicians Certificate of Merit for Outstanding Performance in Medicine, America's Best Physicians, America's Most Honored Doctors, Compassionate Doctor Award, Leading Physicians of the World, and Top 100 Health Professionals Distinction Award. In addition, he was recently honored with the Patients' Choice Recognition Award, given to physicians most highly regarded by their patients. He is also a fellow of the Society for Vascular Medicine and a fellow of the Society of Interventional Radiology.

He is the co-author of the textbook Interventional Oncology which was recently published. In addition to being an expert in endovascular therapy and vascular disease, Dr. Gandhi is one of the interventional oncologists at Miami Cancer Institute and has expertise in minimally invasive therapies for cancer. He is a program director for the International Symposium on Endovascular Therapy (ISET) and Symposium on Clinical Interventional Oncology (CIO).

Alexander Y. Kim, MD

Scientific Advisory Board Member

Dr. Alexander Y. Kim is the Founder and Medical Director of National Vascular Physicians, an out-patient based endovascular and interventional radiology group. He previously served as the Chief of the Division of Interventional Radiology at Georgetown University Medical Center. His research interests include developing novel methods to augment patient outcomes from locoregional therapies.

Rahul Sheth, MD

Scientific Advisory Board Member

Dr. Rahul Sheth is an Associate Professor in the Department of Interventional Radiology at MD Anderson. Rahul received his undergraduate degree in Chemistry and Physics at Harvard University and his MD degree through the Health Sciences and Technology program at Harvard Medical School. After a medicine internship at the University of Pittsburgh, Rahul returned to Boston and completed his residency training in diagnostic radiology as well as fellowship training in Interventional Radiology at Massachusetts General Hospital.

As a clinician-scientist, Rahul studies how locoregional therapies can have positive systemic ramifications for cancer patients. His research interests include optical molecular imaging, tumor microenvironmental factors affecting minimally invasive cancer therapies, photothermal ablation and cancer immunology.

Divya Sridhar, MD

Scientific Advisory Board Member

Dr. Divya Sridhar is Assistant Professor of Radiology at Columbia University Medical Center and Chief of Vascular and Interventional Radiology at Harlem Hospital Center. Divya earned her medical degree at the University of Miami School of Medicine. She completed internship at Memorial Sloan Kettering Cancer Center, residency training at the University of California, San Francisco, and fellowship training in Interventional Radiology at the Mount Sinai Hospital in New York City. Her interests include application of novel technology and techniques to advance minimally invasive image-guided transcatheter and percutaneous treatment of cancer and other conditions.

Sirish Kishore, MD ​

Scientific Advisory Board Member

Dr. Sirish Kishore is a Clinical Assistant Professor at Stanford University Department of Radiology and an Attending Interventional Radiologist within the Palo Alto Veterans Affairs Healthcare System. His interests lie in minimally invasive catheter-based and percutaneous techniques to improve the therapeutic index of cellular and immuno-oncology agents.

Steven C. Katz, MD, FACS

Chief Medical Officer, Scientific Advisory Board Chairman

Dr. Steven C. Katz joined TriSalus in 2018 as Chief Medical Advisor and Chairman of the Scientific Advisory Boards. In September 2020, Steven became the first Chief Medical Officer of TriSalus. Previously, as a full-time academic surgical oncologist, he developed a reputation as a leader in solid tumor immunotherapy, cellular therapeutics, cancer biology, liver immunology and execution of immunotherapy clinical trials. His laboratory has focused on studying liver immunosuppressive cells and strategies for enabling immunotherapy in liver tumors. He also currently serves as Associate Professor of Surgery at the Warren Alpert Medical School of Brown University. His clinical expertise is in the surgical therapy and multi-disciplinary management of liver tumors, pancreas tumors, sarcoma and melanoma.

Steven attended the New York University School of Medicine, received the Alpha Omega Alpha Award, and was inducted into the Alpha Omega Honor Society. He completed his general surgery residency at the New York University Medical Center and was appointed as the Chief Resident. His training included two-year fellowships in Immunology and then Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow. Steven earned his Bachelor of Arts degree at Wesleyan University in Middletown, CT, with a double-major in molecular biology/biochemistry and government.

Steven has received research grants from numerous societies, the NIH and DOD. He has led five solid tumor CAR-T clinical trials, testing novel delivery approaches. He serves as a reviewer for several scientific journals and has served on numerous editorial boards. Steven also participates in NIH study sections and American Board of Surgery exam committees.

SENIOR MANAGEMENT
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARDS

Mary Szela

Chief Executive Officer and President

Mary Szela has nearly 35 years of experience in both the commercial and clinical arenas. Her accomplishments in building billion-dollar businesses, turning around faltering businesses, igniting growth in stagnant businesses and devising innovative, differentiated strategies for undistinguished products make for a remarkable record.

Mary is currently CEO of TriSalus Life Sciences, an immuno-oncology company focused on transforming the way liver and pancreatic tumors are treated. The platform integrates a drug delivery technology with SD-101, a toll-like receptor 9 agonist and other pipeline assets in combination with checkpoint inhibitor therapy to improve patient response rates.

Previously, Mary served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company’s revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus).

Mary held ascending management positions at Abbott Laboratories including President of the company’s $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Senior Vice President for global strategic marketing and services. Mary currently serves as a member of the Board of Directors for Kura Oncology, Prometheus Biosciences, Omega Therapeutics, Senda Biosciences and TriSalus Life Sciences.

She earned an MBA and a BS in nursing, both from the University of Illinois.

Steven C. Katz, MD, FACS

Chief Medical Officer, Scientific Advisory Board Chairman

Dr. Steven C. Katz joined TriSalus in 2018 as Chief Medical Advisor and Chairman of the Scientific Advisory Boards. In September 2020, Steven became the first Chief Medical Officer of TriSalus. Previously, as a full-time academic surgical oncologist, he developed a reputation as a leader in solid tumor immunotherapy, cellular therapeutics, cancer biology, liver immunology and execution of immunotherapy clinical trials. His laboratory has focused on studying liver immunosuppressive cells and strategies for enabling immunotherapy in liver tumors. He also currently serves as Associate Professor of Surgery at the Warren Alpert Medical School of Brown University. His clinical expertise is in the surgical therapy and multi-disciplinary management of liver tumors, pancreas tumors, sarcoma and melanoma.

Steven attended the New York University School of Medicine, received the Alpha Omega Alpha Award, and was inducted into the Alpha Omega Honor Society. He completed his general surgery residency at the New York University Medical Center and was appointed as the Chief Resident. His training included two-year fellowships in Immunology and then Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow. Steven earned his Bachelor of Arts degree at Wesleyan University in Middletown, CT, with a double-major in molecular biology/biochemistry and government.

Steven has received research grants from numerous societies, the NIH and DOD. He has led five solid tumor CAR-T clinical trials, testing novel delivery approaches. He serves as a reviewer for several scientific journals and has served on numerous editorial boards. Steven also participates in NIH study sections and American Board of Surgery exam committees.

Sean Murphy

Chief Financial Officer, Director

Sean Murphy joined TriSalus as Chief Financial Officer in June 2022. Sean has 40+ years of experience in healthcare operations and business development, encompassing pharmaceuticals, medical devices, and diagnostics. He was appointed a director of TriSalus in September 2021, after serving as Executive Vice President of Malin Life Sciences Holdings. A publicly traded investment company, Malin invested in a portfolio of companies that included pharmaceuticals, medical devices, and healthcare services. Additionally, Sean has been a Senior Advisor at Evercore Partners, a leading investment-banking advisory firm. He was also Head of Corporate M&A and Business Development at Abbott Laboratories, where, over 30 years with the company, he played a leading role in strategic and operational investments. Currently, he serves on the board of directors of several life science companies, including Radius Health, Immucor Diagnostics, Xenex and Prenosis.

A CPA, Sean earned an MS in Finance from the University of Illinois and a BBA from Western Illinois University.

Jim Alecxih

President Device Technology

Jim Alecxih has more than 30 years of experience in all aspects of business, focused primarily on biotechnology and medical devices. His expertise includes product development and launch, as well as highly successful international and domestic go-to-market strategies.

Jim is President, Device Technology, for TriSalus Life Sciences, an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. He is responsible for overseeing the growth and development of TriSalus’ TriNav® Infusion System, including device engineering, quality, sales, marketing, and market access.

Prior to joining TriSalus, Jim served as President and CEO at ViveBio Scientific, a biotechnology company focused on specimen transportation and storage, where he raised funding to enable regulatory clearance, manufacturing, and commercialization of a propriety blood plasma separation device. As Chief Commercial Officer of ViewRay, an early-stage radiation oncology company, he led all commercial strategies. Jim spent most of his professional career at Intuitive Surgical, known for their minimally invasive da Vinci surgical systems, where he led successful domestic and international sales teams and exceeded revenue budgets for 51 consecutive quarters over a 14-year period, enabling significant revenue growth for the company.

Jim earned his BA in business administration from LeTourneau University in Longview, Texas.

Bryan F. Cox, PhD

Chief of Research

Dr. Bryan F. Cox joins TriSalus as Chief of Research with an emphasis on pharmaceuticals. Bryan's extensive experience working with due diligence teams as they determine the best path forward from early discovery to first-in-man studies, including involvement in projects resulting in U.S. FDA regulatory approval such as Baxalta®, Gocovri®, Giapreza®, Tricor® and Orilissa®. He has (co-) authored/approved over 250 documents for Regulatory submission and participated in the advancement of over 60 compounds to Phase I clinical trials.

Prior to TriSalus, Bryan was President of CoPharm Global Consulting and spent 17 years at Abbott/Abbvie as Director of Integrative Pharmacology, responsible for both lead optimization and IND-enabling studies. In addition, he was a charter member of the technical assessment team for Abbott BioVentures and spent over 20 years serving on their due diligence teams. Prior to joining Abbott, Bryan was with Rhone Poulenc Rorer. He has published more than 100 papers in peer reviewed journals and has twice been elected to the Council for the American Society of Pharmacology and Experimental Therapeutics.

Bryan received his PhD in Pharmacology from the University of Iowa and is currently an adjunct Professor of Pharmacology at the University of Iowa, College of Medicine.

Jennifer L. Stevens, JD

Chief Regulatory Officer

Jennifer L. Stevens joined TriSalus in March 2021 and serves as Chief Regulatory Officer. Her responsibilities include leading Regulatory Affairs Strategy and Quality Assurance for both the drug and device components of the business. Jennifer brings us expertise in regulatory affairs, law and policy developed during nearly 30 years of advising clients as a regulatory leader in industry, a regulator at the FDA, and an attorney/partner in several law firms, including Kirkland & Ellis, Willkie, Farr & Gallagher, and Pillsbury, where her work included both compliance counseling and transactional work for clients in regulated industries.

Most recently, Jennifer was Executive Director, Immuno-Oncology/Oncology, Global Regulatory Affairs at EMD Serono (Merck KGaA) where she had oversight responsibility for early and late-stage immuno-oncology/oncology assets. Her accomplishments included regulatory approvals globally for Bavencio, an anti-PD1 therapy being developed in collaboration with Merck KGaA/Pfizer, including BLAs/sBLAs (Merkel Cell carcinoma, 2L urothelial carcinoma (UC), Renal Cell carcinoma, and 1L UC maintenance). Jennifer also conducted due diligence for in-licensing/purchase of early/mid/late stage assets.

Prior to joining the pharma industry, Jennifer spent nearly 5 years as Counsel at the FDA, advising on regulations, policy, and agency guidance.

Jennifer received her bachelor’s degree from the University of Illinois and her JD from George Washington University, graduating cum laude from both institutions.

Richard B. Marshak VMD, MBA

Senior Vice President Business Development & Strategy

Dr. Richard B. Marshak joined TriSalus in June 2022 and serves as Senior Vice President, Business Development & Strategy. Richard’s focus is leading the planning and execution of TriSalus’s critical business development and partnership efforts while also envisioning and guiding the SD-101 go-to-market strategy. Richard brings nearly 25 years of experience in the pharmaceutical and biotech space, spanning early discovery through commercialization. During this time, he led a broad range of strategic transactions and had major roles in more than 13 product launches while at Abbott.

Prior to joining TriSalus, Richard was Managing Principal of LF Consulting, providing strategic consulting services to a range of companies, helping to guide critical decisions around product development, corporate development, and commercialization strategies. Richard also served as an Advisor to EMA Partners, a boutique investment bank. During this period he co-founded and served as Chief Business Officer at Nephraegis Therapeutics where he remains on the board of directors. He also served as CEO of Mount Tam Biotechnologies, a biotechnology company spun out of the Buck Institute for Research on Aging, focused on developing novel mTOR modulators to improve the health and well-being of patients suffering from a range of serious diseases.

Prior to this Richard spent 15 years at Abbott/Abbvie in roles spanning marketing, business development, strategic planning, and general management in the Pharmaceutical Products Group. These included General Manager of the Pain Care Franchise and General Manager Alliance Management & Strategic Planning where responsibilities included US business development and global commercial assessment of all licensing opportunities.

Before his time in the pharmaceutical industry, Richard was an equine veterinarian in Pennsylvania. He holds VMD and BA degrees from the University of Pennsylvania and an MBA from the University of Chicago’s Booth School of Business.

Mats Wahlström

Chairman of the Board

Mats Wahlstrom has more than 37 years of experience in the healthcare industry, having served as CEO and CFO of large international companies in the renal field.  Mats currently serves as Executive Chairman of KMG Capital Partners, LLC, Chairman of Breakout Investment Partners, LLC, Chairman of Caduceus Medical Holdings, Inc., and Chairman of Triomed AB, a medical device company. He also serves as the Lead Director of Coherus Biosciences, Inc., a public biotech company. In addition, he serves on the boards of Alteco Medical AB, a public medical device company, and Circuit Clinical Solutions, Inc., a clinical research company.

Mats has also served as a director of Healthgrades, Inc., Zynex, Inc., and Getinge AB, all public companies in the healthcare industry.  From January 2004 through December 2009, Mats served as Co-CEO of Fresenius Medical Care North America, and from November 2002 through December 2009 as President and CEO of Fresenius Medical Services, the largest dialysis provider in the U.S.  Prior to joining Fresenius Medical Care in 2002, he held various positions at Gambro AB in Sweden, including 10 years as CEO of Gambro North America and Gambro Healthcare, Inc., as well as CFO and Executive Vice President of the Gambro Group.

Kerry Hicks

Director

Kerry Hicks currently serves as CEO and President of KMG Capital Partners LLC, a boutique healthcare venture capital company based in Denver, Colorado. As a successful, innovative healthcare executive, Kerry leverages his extensive healthcare and leadership expertise to provide strategic guidance and drive success within portfolio companies.

Prior to joining KMG Capital Partners, Kerry was Founder, Chairman (1998 – 2010) and Chief Executive Officer (1998 – 2012) of Healthgrades. He led Healthgrades through eleven years of consistent growth as a publicly traded company, and then facilitated the sale of the business to Vestar Capital Partners in 2010. Under his leadership, Healthgrades transformed into the premier destination for consumers seeking information on doctors and hospitals. Kerry built Healthgrades from a predecessor company, Specialty Care Network, where he served as President and Chief Executive Officer from 1995 to 1999. From 1985 to 1995 he served as Senior Vice President of LBA Healthcare.

Kerry currently serves as Executive Chairman of Circuit Clinical, Co-Chairman of Breakout Investment Partners, LLC, and serves on the boards of KMG Capital Partners LLC, Caduceus Medical Holdings, Inc. and TriSalus Life Sciences, as well as the Advisory Council of the Institute for Entrepreneurship at Colorado State University, and as a Senior Advisor to both Kitchen One- For-One and the SOX Place, which provide services to at-risk populations in the Denver area.

Diane Parks

Director

Diane Parks joins the TriSalus board with more than 30 years of expertise across the biotech, pharmaceutical, and advertising industries. She’s held executive roles at Kite Pharma Inc, Pharmacyclics, Amgen, and Genentech, most recently serving as senior vice president, marketing and account management at Kite Pharma Inc. Ms. Parks is credited with successfully leading the launch of the first-ever CAR-T therapy, YESCARTA.

She holds a Master of Business Administration degree from Georgia State University and received her Bachelor of Arts degree from Kansas State University. Diane currently serves on several other boards including Calliditas Therapeutics, Kura Oncology, CTI BioPharma and Soligenix, all early-stage biotechnology companies.

Anil Singhal

Director

Dr. Anil Singhal is currently the President and Chief Executive Officer of Trishula Therapeutics, a privately held, clinical-stage company developing TTX-030, a CD39 antibody in multiple solid tumors. Previously, he held a similar role at Adicet Bio, a company developing allogeneic cell therapy in cancer.  He joined Adicet from Canaan Partners where he served as Executive in Residence and OncoResponse Inc., where he served as Chief Scientific Officer. He is the former Vice President of Early Oncology Development of AbbVie and Head of its Abbvie-Redwood City, California site. During his tenure at AbbVie, Anil oversaw the global regulatory approval of Empliciti in multiple myeloma and Daclizumab in multiple sclerosis. As a member of the R&D leadership team, he helped to guide an impressive portfolio and key translational science capabilities in oncology and other diseases.

Anil has held senior roles in the U.S., Japanese and German biopharma/biotechnology industry leading to the approvals of Prosorba in auto-immune disease and talaporfin sodium in non-small cell lung cancer. Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at the University of Washington.

Simone Song

Director

Simone Song is the founder of ORI Capital, and the senior partner of ORI Healthcare Funds which focuses on investing in early-stage and innovative healthcare companies globally.

Simone is the architect of ORIzon, a big data-driven AI research platform which enables ORI Capital to become a quantitative venture capital fund manager that combines quantitative analysis with fundamental research.

Simone serves on the boards of directors of various investee companies of ORI Healthcare Funds, including being the chairman of AffyImmune and being the directors of CG Oncology, Enable Injections, Pillar Biosciences and TriSalus.

Simone was the former Head of Goldman Sachs Healthcare Investment Banking for Greater China. Prior to joining Goldman Sachs, she was a Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers and an executive board advisor to AXA Asia Pacific Holdings.

Simone received a BA in Economics from Fudan University in China and a MA in Economics from Claremont Graduate School.

John L. Tullis

Director

John L. Tullis is CEO at Tullis Health Investors, an institutional investment fund manager focused on rapidly growing, primarily private, emerging healthcare companies with breakthrough innovations.  His focus is to create impact by helping companies accelerate the process of scaling their technologies, therapies, and services into widespread commercial markets.  He has more than 26 years of investing experience. John currently serves as an independent board member of Intrivo Diagnostics.  He was also an Executive Committee Member of the Board of Directors of the Beacon Council, Miami-Dade’s Economic Development Organization, for three years.

John holds a Bachelor’s degree in Liberal Arts from DePauw University. He received a Graduate Certificate from the University of Virginia’s McIntire Business Institute and a Master’s degree in Business Administration from the University of Miami.

Sean Murphy

Chief Financial Officer, Director

Sean Murphy joined TriSalus as Chief Financial Officer in June 2022. Sean has 40+ years of experience in healthcare operations and business development, encompassing pharmaceuticals, medical devices, and diagnostics. He was appointed a director of TriSalus in September 2021, after serving as Executive Vice President of Malin Life Sciences Holdings. A publicly traded investment company, Malin invested in a portfolio of companies that included pharmaceuticals, medical devices, and healthcare services. Additionally, Sean has been a Senior Advisor at Evercore Partners, a leading investment-banking advisory firm. He was also Head of Corporate M&A and Business Development at Abbott Laboratories, where, over 30 years with the company, he played a leading role in strategic and operational investments. Currently, he serves on the board of directors of several life science companies, including Radius Health, Immucor Diagnostics, Xenex and Prenosis.

A CPA, Sean earned an MS in Finance from the University of Illinois and a BBA from Western Illinois University.

Mary Szela

Chief Executive Officer and President

Mary Szela has nearly 35 years of experience in both the commercial and clinical arenas. Her accomplishments in building billion-dollar businesses, turning around faltering businesses, igniting growth in stagnant businesses and devising innovative, differentiated strategies for undistinguished products make for a remarkable record.

Mary is currently CEO of TriSalus Life Sciences, an immuno-oncology company focused on transforming the way liver and pancreatic tumors are treated. The platform integrates a drug delivery technology with SD-101, a toll-like receptor 9 agonist and other pipeline assets in combination with checkpoint inhibitor therapy to improve patient response rates.

Previously, Mary served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company’s revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus).

Mary held ascending management positions at Abbott Laboratories including President of the company’s $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Senior Vice President for global strategic marketing and services. Mary currently serves as a member of the Board of Directors for Kura Oncology, Prometheus Biosciences, Omega Therapeutics, Senda Biosciences and TriSalus Life Sciences.

She earned an MBA and a BS in nursing, both from the University of Illinois.

Scientific Advisory Board - Oncology

Richard D Carvajal, MD

Scientific Advisory Board Member

Dr. Richard D. Carvajal is an Associate Professor of Medicine at Columbia University Irving Medical Center where he serves as both Director of Experimental Therapeutics and Director of the Melanoma Service within the Division of Hematology/Oncology. He serves as Co-Leader of the Precision Oncology and Systems Biology Program within the Herbert Irving Comprehensive Cancer Center.

Richard’s research is focused on the development of novel therapies for patients with melanoma and other cancers, with the overall objective of controlling and curing these diseases. To achieve this goal, he has used our increasing knowledge of the underlying biology of cancer to rapidly integrate this knowledge, novel targeted and immunotherapeutic agents, and efficient trial design in order to improve the outcomes of cancer patients everywhere. Richard's melanoma research has included the study and treatment of uncommon clinical and molecular subsets of melanoma such as melanomas arising from the eye (uveal melanomas), from the mucosal surfaces of the body (mucosal melanomas), and from the palms of the hands, soles of the feet or under the fingernails (acral melanomas).

He has been the principal investigator or co-investigator of over 500 clinical trials, including a number of investigator-initiated, multi-center, Cancer Therapy Evaluation Program (CTEP) sponsored and industry-supported clinical trials. His research has been supported by the National Cancer Institute, the Food and Drug Administration, the Conquer Cancer Foundation, the Melanoma Research Alliance, the Melanoma Research Foundation and the Empire Clinical Research Investigator Program. He has authored or co-authored more than 200 peer-reviewed manuscripts, books, and book chapters.

In addition to Richard's work at Columbia University Irving Medical Center, he serves as the co-chair of the International Rare Cancer Initiative Uveal Melanoma working group, a joint initiative between the National Cancer Institute, the European Organization for Research and Treatment of Cancer, and the Cancer Research UK to enhance international collaboration in the conduct of clinical trials for uveal melanoma.

Christopher Crane, MD

Scientific Advisory Board Member

Dr. Christopher Crane is a Vice Chair of the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) specializing in gastrointestinal cancers. Prior to joining MSKCC, he served as Program Director/Chief of the Gastrointestinal Section, and Program Director of the Residency and Fellowship training programs in the Department of Radiation Oncology at the University of Texas M. D. Anderson Cancer Center.

Christopher is leading several cancer clinical trials across the country. He is interested in the role of radiation dose escalation using novel technologies in the treatment of liver and pancreatic cancers. He has helped develop technologies that allow administration of higher doses of radiation in GI malignancies and states that technology such as image guidance has helped with the challenge of internal organ motion.

Christopher has been involved with the NCI-Gastrointestinal Steering Committee, NRG Oncology Group, ASTRO, ASCO, Locally advanced and Advanced Pancreatic Clinical Practice Guidelines and the Emeritus Scientific and Medical Advisory Board of PANCAN.

Sapna Patel, BA, MD

Scientific Advisory Board Member

Dr. Sapna Patel is a medical oncologist and Associate Professor, Director of the Uveal Melanoma Program, and Melanoma Fellowship Program Director at the University of Texas MD Anderson Cancer Center in Houston, Texas specializing in uveal, cutaneous, and mucosal melanoma with one of the largest metastatic uveal melanoma practices in the world.

Sapna has led several investigator-initiated and multi-institutional clinical trials, including studies of targeted therapy, immunotherapy, T-cell therapy, and antibody-drug conjugates for uveal melanoma. Her lab work focuses on translational research, characterizing longitudinal molecular signatures in tumor samples from patients receiving treatment. She also leads several cutaneous melanoma projects with SWOG and serves as Melanoma Chair for SWOG. She has received intramural and extramural funding including NIH grants. Her goal is to develop effective therapies for adjuvant and metastatic settings, and to identify biomarkers to predict clinical benefit.

Vincent Picozzi, MD

Scientific Advisory Board Member

Dr. Vincent J. Picozzi is Director for the Pancreaticobiliary Program at Virginia Mason Medical Center. A summa cum laude, Phi Beta Kappa graduate from Yale University, Vincent obtained his MD degree from Stanford University, did his internship and residency at Harvard University (Brigham and Women's Hospital) and fellowships in hematology and oncology again at Stanford. He also holds a Master’s degree in Medical Management, Delta Omega, from Tulane University. Vincent was an instructor in hematology and oncology at Stanford for two years before joining Virginia Mason, where he has been for the past 36 years.

Vincent has one of the largest pancreaticobiliary oncology practices in the United States. He has received numerous accolades as a clinician, including designation as one of Seattle’s Best Doctors and one of America’s Top Cancer Doctors for the last fifteen consecutive years (2008-2022). He also directs an active, comprehensive clinical and translational research program in pancreaticobiliary cancer at Virginia Mason and has published nearly 200 papers and abstracts.

Vincent has educational committees for the GI Oncology Symposium and ASCO for non-colorectal cancers and served as Educational Chair for both in 2016. He has been a featured speaker at virtually every major clinical oncologic meeting in the United States, including ASCO (the American Society of Clinical Oncology), ASH (the American Society of Hematology), ASTRO (the American Society of Therapeutic Radiation Oncology), Digestive Diseases Week, AHPBA (The American Hepatopancreaticobiliary Association), ACOS (the American College of Surgeons), the Best of ASCO, the GI Oncology Symposium and the World Pancreas Symposium.

Vincent also has held a number of leadership positions with national and regional organizations, including ASCO, ASH, the American College of Surgeons Oncology Group (ACOSOG), the Pancreatic Cancer Action Network where he is a past chairman and current board member for the Scientific and Medical Advisory Board, the Pancreas Cancer Research Team (PCRT-Executive Committee) and the Providence Hospice of Seattle (Executive Board). He also has proudly served on the Executive Board of the Washington State Medical Oncology Society since its inception 30 years ago, twice serving as president. Recently, Vincent is the co-principal investigator and Clinical Trials Consortium chairman of the new Precision Promise Clinical Research Consortium sponsored by the Pancreatic Cancer Action Network.

Venu G. Pillarisetty, MD

Scientific Advisory Board Member

A Professor of Hepatopancreatobiliary Surgical Oncology at the University of Washington and the Fred Hutchinson Cancer Center, Dr. Venu G. Pillarisetty treats patients with pancreatic cancer and other diseases involving the pancreas. He attended Columbia University College of Physicians and Surgeons, did his General Surgery residency at the University of Massachusetts, and completed fellowships in Tumor Immunology and Surgical Oncology at Memorial Sloan-Kettering Cancer Center prior to joining the faculty at the University of Washington.

Funded by the NIH, the DoD, and several industry partnerships, Venu's research laboratory work using cultured slices of fresh human tumors has revealed unique targetable aspects of tumor immunobiology. As a clinical trialist, he is actively working to translate his laboratory findings to patient care through NIH cooperative group studies.

Marlana M Orloff, MD

Scientific Advisory Board Member

Dr. Marlana Orloff is an associate professor of medicine and medical oncologist at Thomas Jefferson University Hospital – Sidney Kimmel Cancer Center in Philadelphia, PA. Her clinical and research focus is on primary and advanced melanomas. Her main interest is in rare melanomas including uveal, conjunctival and mucosal melanoma.

Marlana's research is centered on investigating the epidemiology of uveal melanoma and discovery of novel therapies for primary and advanced uveal, conjunctival, mucosal and cutaneous melanoma. She works very closely with the team at Wills Eye Hospital to manage hundreds of patients with primary and metastatic ocular melanoma. Marlana is a member of a multidisciplinary team of medical oncologists, interventional radiologists, radiation oncologist and numerous other essential personnel that treats patients with metastatic uveal melanoma from all over the country. She is principal and co-investigator on a number of clinical trials enrolling patients with primary and advanced melanomas of all types.

Mike Pishvaian, MD, PhD

Scientific Advisory Board Member

Dr. Mike Pishvaian is an Associate Professor in the Department of Oncology at Johns Hopkins University.  Mike is an MD and has a PhD in Tumor Biology, having earned both degrees at Georgetown in 2001.  He remained at Georgetown after graduation, completing his medical residency in 2004, then his fellowship in Hematology/Oncology in 2007.  He served on the faculty at Georgetown until moving to MD Anderson in 2019.  At MD Anderson, he was the co-director for Clinical Research at the Zayed Center for Pancreatic Cancer Research.  He then moved to Johns Hopkins, and is the Director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs at the National Capital Region Cancer Center.

Mike is a translational oncologist, focused on providing novel therapies for patients, particularly in the areas of pancreatic cancer and refractory colorectal cancer.  His work has been focused in the area of precision medicine, with a special focus on therapy targeted towards homologous recombination DNA repair deficient tumors, and Mike is a Co-investigator on an NIH RO1 to study mechanisms of resistance to PARP inhibitor-based therapy, and a Co-PI of a U01 grant aimed at studying ex vivo patient derived models of cancer for patients with pancreatic cancer.

Steven C. Katz, MD, FACS

Chief Medical Officer, Scientific Advisory Board Chairman

Dr. Steven C. Katz joined TriSalus in 2018 as Chief Medical Advisor and Chairman of the Scientific Advisory Boards. In September 2020, Steven became the first Chief Medical Officer of TriSalus. Previously, as a full-time academic surgical oncologist, he developed a reputation as a leader in solid tumor immunotherapy, cellular therapeutics, cancer biology, liver immunology and execution of immunotherapy clinical trials. His laboratory has focused on studying liver immunosuppressive cells and strategies for enabling immunotherapy in liver tumors. He also currently serves as Associate Professor of Surgery at the Warren Alpert Medical School of Brown University. His clinical expertise is in the surgical therapy and multi-disciplinary management of liver tumors, pancreas tumors, sarcoma and melanoma.

Steven attended the New York University School of Medicine, received the Alpha Omega Alpha Award, and was inducted into the Alpha Omega Honor Society. He completed his general surgery residency at the New York University Medical Center and was appointed as the Chief Resident. His training included two-year fellowships in Immunology and then Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow. Steven earned his Bachelor of Arts degree at Wesleyan University in Middletown, CT, with a double-major in molecular biology/biochemistry and government.

Steven has received research grants from numerous societies, the NIH and DOD. He has led five solid tumor CAR-T clinical trials, testing novel delivery approaches. He serves as a reviewer for several scientific journals and has served on numerous editorial boards. Steven also participates in NIH study sections and American Board of Surgery exam committees.

Scientific Advisory Board - Radiology

Jordan Tasse, MD

Scientific Advisory Board Member

Dr. Jordan Tasse is the director of interventional oncology and an associate professor of vascular and interventional radiology at Rush University Medical Center in Chicago, Illinois.  His practice focuses on minimally invasive cancer treatments throughout the body including the liver, lung,  pancreas and kidney. Jordan is currently involved in multiple clinical research projects including trans-arterial cancer therapies, ablative treatments and immunotherapy.

Terence Gade, MD, PhD

Scientific Advisory Board Member

Dr. Terence Gade is Assistant Professor of Radiology, Penn Presbyterian Medical Center, Attending, Hospital of the University of Pennsylvania, and Assistant Investigator, Abramson Cancer Research Institute. Terence co-founded the Penn Image-Guided Interventions (PIGI) Laboratory. The interests of the laboratory focus on translational research for the development of novel imaging approaches and advanced therapeutics.

Ripal Gandhi, MD

Scientific Advisory Board Member

Dr. Ripal Gandhi did his undergraduate studies at Northwestern University and Harvard University. He graduated summa cum laude (highest honors). He received his degree in medicine from Northwestern University Medical School, where he also graduated with honors. Following medical school, he completed a surgical internship at Cornell University Medical Center and New York Presbyterian Hospital. He completed his residency training and fellowship at UCLA Medical Center. Currently, he is an associate clinical professor at the University of South Florida School of Medicine and FIU Herbert Wertheim College of Medicine. Ripal regularly trains other physicians in various vascular/endovascular, interventional radiology, and interventional oncology techniques.

Because of his interest in discovering new therapies, Ripal also dedicated an entire year to biomedical research at the renowned Memorial Sloan-Kettering Cancer Center in New York. At Sloan-Kettering, he investigated chemoembolization and other minimally invasive therapies for liver cancer and other malignancies. He also served as a research fellow at the National Institutes of Health (NIH). He has published his findings in several scientific journals, including the Journal of Vascular and Interventional Radiology, Journal of Vascular Surgery, Vascular Medicine, Interventional Cardiology, and Journal of the American College of Surgeons. He also authored several textbook chapters and presented his research at national and international meetings.

Prior to joining Miami Cardiac & Vascular Institute, he was an international visiting scholar at Asan Medical Center/University of Ulsan Medical School in Seoul, South Korea. As an international scholar, he gave several lectures and furthered his expertise in innovative minimally invasive therapies.

Ripal is the recipient of multiple awards, including the American College of Physicians Certificate of Merit for Outstanding Performance in Medicine, America's Best Physicians, America's Most Honored Doctors, Compassionate Doctor Award, Leading Physicians of the World, and Top 100 Health Professionals Distinction Award. In addition, he was recently honored with the Patients' Choice Recognition Award, given to physicians most highly regarded by their patients. He is also a fellow of the Society for Vascular Medicine and a fellow of the Society of Interventional Radiology.

He is the co-author of the textbook Interventional Oncology which was recently published. In addition to being an expert in endovascular therapy and vascular disease, Dr. Gandhi is one of the interventional oncologists at Miami Cancer Institute and has expertise in minimally invasive therapies for cancer. He is a program director for the International Symposium on Endovascular Therapy (ISET) and Symposium on Clinical Interventional Oncology (CIO).

Alexander Y. Kim, MD

Scientific Advisory Board Member

Dr. Alexander Y. Kim is the Founder and Medical Director of National Vascular Physicians, an out-patient based endovascular and interventional radiology group. He previously served as the Chief of the Division of Interventional Radiology at Georgetown University Medical Center. His research interests include developing novel methods to augment patient outcomes from locoregional therapies.

Rahul Sheth, MD

Scientific Advisory Board Member

Dr. Rahul Sheth is an Associate Professor in the Department of Interventional Radiology at MD Anderson. Rahul received his undergraduate degree in Chemistry and Physics at Harvard University and his MD degree through the Health Sciences and Technology program at Harvard Medical School. After a medicine internship at the University of Pittsburgh, Rahul returned to Boston and completed his residency training in diagnostic radiology as well as fellowship training in Interventional Radiology at Massachusetts General Hospital.

As a clinician-scientist, Rahul studies how locoregional therapies can have positive systemic ramifications for cancer patients. His research interests include optical molecular imaging, tumor microenvironmental factors affecting minimally invasive cancer therapies, photothermal ablation and cancer immunology.

Divya Sridhar, MD

Scientific Advisory Board Member

Dr. Divya Sridhar is Assistant Professor of Radiology at Columbia University Medical Center and Chief of Vascular and Interventional Radiology at Harlem Hospital Center. Divya earned her medical degree at the University of Miami School of Medicine. She completed internship at Memorial Sloan Kettering Cancer Center, residency training at the University of California, San Francisco, and fellowship training in Interventional Radiology at the Mount Sinai Hospital in New York City. Her interests include application of novel technology and techniques to advance minimally invasive image-guided transcatheter and percutaneous treatment of cancer and other conditions.

Sirish Kishore, MD ​

Scientific Advisory Board Member

Dr. Sirish Kishore is a Clinical Assistant Professor at Stanford University Department of Radiology and an Attending Interventional Radiologist within the Palo Alto Veterans Affairs Healthcare System. His interests lie in minimally invasive catheter-based and percutaneous techniques to improve the therapeutic index of cellular and immuno-oncology agents.

Steven C. Katz, MD, FACS

Chief Medical Officer, Scientific Advisory Board Chairman

Dr. Steven C. Katz joined TriSalus in 2018 as Chief Medical Advisor and Chairman of the Scientific Advisory Boards. In September 2020, Steven became the first Chief Medical Officer of TriSalus. Previously, as a full-time academic surgical oncologist, he developed a reputation as a leader in solid tumor immunotherapy, cellular therapeutics, cancer biology, liver immunology and execution of immunotherapy clinical trials. His laboratory has focused on studying liver immunosuppressive cells and strategies for enabling immunotherapy in liver tumors. He also currently serves as Associate Professor of Surgery at the Warren Alpert Medical School of Brown University. His clinical expertise is in the surgical therapy and multi-disciplinary management of liver tumors, pancreas tumors, sarcoma and melanoma.

Steven attended the New York University School of Medicine, received the Alpha Omega Alpha Award, and was inducted into the Alpha Omega Honor Society. He completed his general surgery residency at the New York University Medical Center and was appointed as the Chief Resident. His training included two-year fellowships in Immunology and then Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow. Steven earned his Bachelor of Arts degree at Wesleyan University in Middletown, CT, with a double-major in molecular biology/biochemistry and government.

Steven has received research grants from numerous societies, the NIH and DOD. He has led five solid tumor CAR-T clinical trials, testing novel delivery approaches. He serves as a reviewer for several scientific journals and has served on numerous editorial boards. Steven also participates in NIH study sections and American Board of Surgery exam committees.

Our History

Dr. Steven Katz, MD, had operated on thousands of cancer patients and studied liver immune cells for nearly two decades. After years of clinical work and research, he was seeking answers to a fundamental question: How can we help more patients with liver and pancreatic tumors benefit from immunotherapy?

At the time, our company had been developing and commercializing an innovative new device technology and approach to administering therapeutics called Pressure-Enabled Drug Delivery™ (PEDD™). Dr. Katz saw its potential for use in liver tumors, and he led a phase 1 clinical trial using our PEDD approach to administer cell therapy.1 The clinical results were promising, and Dr. Katz joined us as our CMO.

In over 16,000 procedures, PEDD has been used to improve intravascular therapeutic delivery by modulating pressure and flow to enhance local drug concentrations in tumors. This is a helpful step forward in the treatment of pancreatic and liver tumors. However, in addition to effective drug delivery, we’ve come to believe that overcoming immunosuppression in these organs is also important to successful immunotherapy. Because of this, we’ve launched a platform approach that combines our innovative device technology with therapeutics. In 2020 we acquired SD-101, an investigational toll-like receptor 9 (TLR9) agonist. In early studies, SD-101 has demonstrated the reversal of immunosuppression and promotion of responses to other forms of immunotherapy like checkpoint inhibitors.2

In September 2021, we initiated our clinical development program by enrolling the first patients in the Pressure Enabled Regional Immuno-Oncology (PERIO™-01) clinical study evaluating the TriSalus platform in adults with uveal melanoma with liver metastases. We followed with PERIO™-02, which studies SD-101 for the treatment of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).

We’re now moving forward in additional indications including primary liver and pancreatic cancers. We believe we have the potential to transform the treatment of these diseases.

Science

The TriSalus™ integrated approach aims to address two of the most significant barriers to treatment.

  • LEARN MORE
Platform

We are taking an integrated approach to treating liver and pancreatic tumors.

  • LEARN MORE

Our Pipeline

Our research is focused on improving outcomes for patients. We have multiple clinical trials in progress as we study an innovative, therapeutic approach combining immunomodulation therapy with proprietary intravascular regional delivery.

PIPELINE

CITATIONS

  1. Katz SC, et al. J Immunother Cancer. 2020;8(2):e001097.
  2. Ribas A, et al. Cancer Discov. 2018;8(10):1250-1257.
© 2023 TriSalus Life Sciences, Inc. All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Linkedin Twitter
Linkedin Twitter
© 2023 TriSalus Life Sciences, Inc.
All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Employee Name
Employee Tags

Employee Info

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

YES
CANCEL